Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Case Evaluation & Legal Options
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Occupational Exposure
The legacy of general health and science information has long served as a foundation for public understanding of medical treatments and their associated risks. Within this broad context, the dissemination of knowledge about therapeutic interventions, including disease-modifying therapies, has empowered individuals to make informed decisions regarding their care. This heritage emphasizes the importance of awareness and vigilance in the face of potential adverse effects, fostering a culture of proactive health management. Transitioning from this general framework, a specific area of concern emerges in the context of occupational exposure to Tysabri (natalizumab) and the risk of Progressive Multifocal Leukoencephalopathy (PML). While the general health paradigm addresses patient-centered risks, the occupational dimension introduces a distinct set of considerations for professionals who may handle, administer, or come into contact with this medication in clinical or research settings. These individuals face potential exposure through accidental needlesticks, spills, or inhalation of aerosolized particles, raising questions about workplace safety protocols and legal recourse. The pivot from general health information to occupational exposure highlights the need for specialized legal evaluation, where attorneys assess liability, workers' compensation claims, and employer responsibilities. Understanding the legal options available to those affected by Tysabri-related PML in an occupational context requires careful case evaluation, focusing on exposure circumstances and applicable regulations.
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing them from crossing the blood-brain barrier into the central nervous system. This reduces inflammation in the brain, which is beneficial for controlling multiple sclerosis relapses, but it also impairs immune surveillance against JCV. Without adequate immune cell trafficking into the brain, latent JCV can reactivate and cause PML. Evidence from postmarketing surveillance in Japan, where a nationwide PML surveillance committee requires mandatory registration of all natalizumab cases, documented 8 cases of natalizumab-associated PML between 2016 and 2024 (https://pubmed.ncbi.nlm.nih.gov/40875960/). Of these, 5 were classified as clinically definite PML cases, all in women with relapsing-remitting multiple sclerosis (https://pubmed.ncbi.nlm.nih.gov/40875960/). This demonstrates that PML can occur even with extended interval dosing, a strategy sometimes used to reduce risk. The clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and sometimes seizures. Diagnosis typically involves brain imaging, lumbar puncture to detect JCV DNA in cerebrospinal fluid, and sometimes brain biopsy. The boxed warning instructs healthcare professionals to monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML and to withhold Tysabri dosing immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Legal Considerations for Tysabri-Related PML
Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks associated with Tysabri, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML after Tysabri treatment, legal options may be available. The adequacy of warnings regarding Tysabri and PML is a central consideration. The FDA boxed warning explicitly states that Tysabri increases the risk of PML and lists known risk factors. However, patients and their families may question whether the warnings were sufficiently communicated or whether the risk was adequately weighed against the expected benefit in their specific case. Attorney-related considerations for affected patients include evaluating whether the prescribing physician followed the TOUCH program requirements, whether the patient was properly monitored for signs of PML, and whether the timing of diagnosis and treatment withdrawal was appropriate. The timeline between Tysabri exposure and documented harm can vary. The boxed warning notes that duration of therapy is a risk factor, and postmarketing reports indicate that PML can occur after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In the Japanese surveillance study, cases were identified over an 8-year period, suggesting that prolonged exposure increases risk (https://pubmed.ncbi.nlm.nih.gov/40875960/). Early detection and immediate withdrawal of Tysabri are critical, as the boxed warning mandates withholding the drug at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients considering legal action should consult with an attorney experienced in pharmaceutical injury cases. A Tysabri injury lawyer can help evaluate whether the harm resulted from inadequate warnings, failure to monitor, or other factors. Case evaluation typically involves reviewing medical records, treatment history, and documentation of risk communication. The outcome of PML is often severe, with most cases leading to death or permanent disability, making legal options a critical consideration for affected patients and their families.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is Tysabri and why does it carry a PML risk?
Tysabri (natalizumab) is a medication used as monotherapy for relapsing forms of multiple sclerosis. It carries a known risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the John Cunningham virus. The FDA has assigned a boxed warning due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What legal options are available for someone who developed PML after Tysabri?
Legal options may include claims for inadequate warnings, failure to monitor, or negligence in prescribing. An experienced Tysabri injury lawyer can evaluate whether the prescribing physician followed the TOUCH program requirements and whether the patient was properly monitored. Case evaluation involves reviewing medical records and risk communication documentation.
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.